Jianfeng Health won many honorary titles such as "Science and Technology Small and Medium-sized Enterprises in Zhejiang Province"
Release time:
2020-08-14
Peak Health has won many honorary titles such as "Zhejiang Science and Technology Small and Medium-sized Enterprises"
News Recently, Peak Health has been awarded several plaques and certificates by Zhejiang Science and Technology Department, Jinhua Municipal People's Government and Jinhua Municipal Science and Technology Bureau, namely "Zhejiang Science and Technology Small and Medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprise" and Technology Research and Development Center.
According to relevant requirements, small and medium-sized science and technology enterprises in Zhejiang Province must be small and medium-sized micro-enterprises with independent intellectual property rights, proprietary technology or advanced knowledge and engaged in the research, development, production, sales and service of high-tech and its products. The proportion of personnel engaged in scientific and technological research and development in the total number of employees in that year is not less than 10% . Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016 , a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patents and 5 appearance patents had been obtained.
High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State '', continue to carry out research and development and technological achievements transformation, and their main products (services) have independent intellectual property rights (authorized, registered or Accepted), there are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the intensive processing technology and equipment of agricultural products, three series of products of traditional Chinese medicine, plant extracts and health food, mainly using traditional Chinese medicine and fruits and vegetables as raw materials. give full play to the advantages of authentic medicinal materials, tap the characteristic connotation, effectively promote the development of agricultural products processing industry, accelerate the process of local agricultural industrialization, and promote the development of agriculture and rural economy.
Jinhua Agricultural Science and Technology Research and Development Center needs to pay attention to industry-university-research cooperation, transform the existing research results of enterprises into products that meet market demand, increase investment in scientific research, and develop products with high "gold content" and strong market adaptability. Jianfeng Health has established long-term cooperative relations of scientific research and development and achievement transformation with China Pharmaceutical University, Shenyang Pharmaceutical University, Tianjin University and other well-known domestic scientific research institutions. At present, it has a batch of advanced R & D equipment such as high performance liquid chromatograph, ultraviolet spectrophotometer, supercritical extraction, column chromatography, membrane separation, freeze-drying, etc, undertook two scientific and technological research and development projects, "Pilot-scale process study on the extraction of natural high-efficiency antioxidant ergothioneine from mushrooms" and "Industrialization technology research on the extraction of resveratrol and its oligomers from grapevines.
The achievement of these honors has further promoted Jianfeng Health to improve its independent technological innovation capability and accelerated its development into an intellectual property advantage enterprise. It is reported that the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City will also give different standards of financial rewards to enterprises that have obtained honorary titles. (Xu Feng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page